Alterity Therapeutics Limited(ATHE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ATHE Alterity Therapeutics Limited

Market Closed 02-14 16:00:00 EST

4.42

+0.00

0.00%

盘后4.38

-0.04-0.90%

19:33 EST

High4.50	Low4.28	Vol58.88K
Open4.38	D1 Closing4.42	Amplitude4.98%
Mkt Cap39.19M	Tradable Cap34.82M	Total Shares8.87M
T/O261.51K	T/O Rate0.75%	Tradable Shares7.88M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ATHE","market":"US","secType":"STK","nameCN":"Alterity Therapeutics Limited","latestPrice":4.42,"timestamp":1739566800000,"preClose":4.42,"halted":0,"volume":58880,"hourTrading":{"tag":"盘后","latestPrice":4.38,"preClose":4.42,"latestTime":"19:33 EST","volume":16181,"amount":72824.81,"timestamp":1739579598458},"delay":0,"floatShares":7878500,"shares":8867226,"eps":-2.097678,"marketStatus":"Market Closed","change":0,"latestTime":"02-14 16:00:00 EST","open":4.38,"high":4.5,"low":4.28,"amount":261512.2816,"amplitude":0.049774,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.097678,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1739869200000},"marketStatusCode":7,"adr":0,"adrRate":600,"exchange":"NASDAQ","adjPreClose":4.42,"preHourTrading":{"tag":"盘前","latestPrice":4.28,"preClose":4.42,"latestTime":"09:09 EST","volume":275,"amount":1210.056375,"timestamp":1739542194045},"postHourTrading":{"tag":"盘后","latestPrice":4.38,"preClose":4.42,"latestTime":"19:33 EST","volume":16181,"amount":72824.81,"timestamp":1739579598458},"volumeRatio":0.5306646282720726},"requestUrl":"/m/hq/s/ATHE","defaultTab":"news","newsList":[{"id":"2510785913","title":"Alterity Therapeutics raises A$40M in placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2510785913","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510785913?lang=en_us&edition=fundamental","pubTime":"2025-02-10 20:31","pubTimestamp":1739190660,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics (ATHE) has received binding commitments for a capital raising of A$40M via a two tranche placement of fully paid ordinary sha...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-raises-a40m-in-placement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-raises-a40m-in-placement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATHE","LENZ","BK4139"],"gpt_icon":0},{"id":"2510859697","title":"Alterity Therapeutics Raises A$40.0 million in Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2510859697","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510859697?lang=en_us&edition=fundamental","pubTime":"2025-02-10 20:25","pubTimestamp":1739190300,"startTime":"0","endTime":"0","summary":"– Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders – – Capital raising was strongly supported by domestic and international institutional investors – MELBOURNE, Au","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/10/3023336/0/en/Alterity-Therapeutics-Raises-A-40-0-million-in-Placement.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATHE","LU2125909916.SGD","LENZ","LU0757428866.USD","BK4143","LU0053671581.USD","LU0728928796.USD","LU1923622291.USD","LU2211815571.USD","MSA","LU1815336091.USD","LU2125909759.SGD"],"gpt_icon":0},{"id":"2509250420","title":"Alterity Therapeutics Ltd (ADR) trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2509250420","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509250420?lang=en_us&edition=fundamental","pubTime":"2025-02-06 06:35","pubTimestamp":1738794924,"startTime":"0","endTime":"0","summary":"17:30 EST Alterity Therapeutics (ATHE) Ltd (ADR) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-ltd-adr-trading-halted-news-pending-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-ltd-adr-trading-halted-news-pending-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATHE","LENZ","BK4139"],"gpt_icon":0},{"id":"2508112043","title":"Benchmark Downgrades Alterity Therapeutics to Hold From Speculative Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2508112043","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508112043?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:26","pubTimestamp":1738585603,"startTime":"0","endTime":"0","summary":"Benchmark Downgrades Alterity Therapeutics to Hold From Speculative Buy","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","ATHE"],"gpt_icon":0},{"id":"2507604350","title":"Alterity Therapeutics Is Maintained at Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2507604350","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507604350?lang=en_us&edition=fundamental","pubTime":"2025-01-31 07:00","pubTimestamp":1738278000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ATHE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 30, 2025 18:00 ET (23:00 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATHE","ATH.AU","LENZ"],"gpt_icon":0},{"id":"2507609958","title":"Alterity Therapeutics (ASX:ATH) shareholder returns have been stellar, earning 260% in 1 year","url":"https://stock-news.laohu8.com/highlight/detail?id=2507609958","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507609958?lang=en_us&edition=fundamental","pubTime":"2025-01-31 05:58","pubTimestamp":1738274326,"startTime":"0","endTime":"0","summary":"The most you can lose on any stock  is 100% of your money. But when you pick a company that is really flourishing, you can make more than 100%. For example, the Alterity Therapeutics Limited  share price had more than doubled in just one year - up 260%. Shareholders are also celebrating an even better 500% rise, over the last three months. In contrast, the longer term returns are negative, since the share price is 14% lower than it was three years ago.Since the stock has added AU$48m to its market cap in the past week alone, let's see if underlying performance has been driving long-term returns.We think companies that have neither significant revenues nor profits are pretty high risk. You should be aware that the company needed to issue more shares recently so that it could raise enough money to continue pursuing its business plan. While some such companies do very well over the long term, others become hyped up by promoters before eventually falling back down to earth, and going bankr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alterity-therapeutics-asx-ath-shareholder-215846964.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4139","ATHE","LENZ","ATH","BK7067","ATH.AU","BK4162"],"gpt_icon":0},{"id":"2507282674","title":"Sector Update: Health Care Stocks Gain in Afternoon Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2507282674","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507282674?lang=en_us&edition=fundamental","pubTime":"2025-01-31 03:07","pubTimestamp":1738264069,"startTime":"0","endTime":"0","summary":"Health care stocks rose Thursday afternoon, with the NYSE Health Care Index adding 1.4% and the Health Care Select Sector SPDR Fund  climbing 1.3%.The iShares Biotechnology ETF  advanced 1.4%.In corporate news, Alterity Therapeutics  shares surged past 51% after the company said its ATH434 lead candidate demonstrated 48% slowing of clinical progression in a phase 2 trial in people with early-stage multiple system atrophy.Tectonic Therapeutic  shares soared 94% after it said a phase 1b trial showed that TX45 improved left ventricular function and pulmonary hemodynamics.Cigna  shares fell 8.1% after it reported a decline in Q4 adjusted earnings, which also missed market expectations.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B19Z3581.USD","BK4585","LU0289739699.SGD","BK4139","IBB","LU0058720904.USD","TECX","LU1059921491.USD","IE0002270589.USD","ATHE","LU0868494617.USD","IE00BSNM7G36.USD","BK4196","XLV","LU1261432733.SGD","BK4581","BK4588","IE00B19Z3B42.SGD","CI"],"gpt_icon":0},{"id":"2507809672","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2507809672","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507809672?lang=en_us&edition=fundamental","pubTime":"2025-01-31 02:45","pubTimestamp":1738262707,"startTime":"0","endTime":"0","summary":"Alpha Modus  Chief Executive William Alessi emphasized Thursday the company's \"strong\" fundamentals and an \"ongoing\" growth strategy amid \"uninformed speculation\" by certain market participants.\"The recent sell-side activity targeting AMOD stock appears to be driven by misconceptions and a lack of understanding about our business and long-term strategy coupled with the 'de-SPAC norm,'\" Alessi said in a company statement.Tectonic Therapeutic  shares surged 109% after the company said Thursday a phase 1b trial showed that a single intravenous dose of TX45 resulted in \"meaningful improvements\" in left ventricular function and pulmonary hemodynamics.Over 4.3 million shares traded intraday versus a daily average of nearly 144,000.Alterity Therapeutics  said Thursday its ATH434 lead candidate demonstrated 48% slowing of clinical progression in a phase 2 clinical trial in patients with early-stage multiple system atrophy.Shares jumped 50% as intraday trading volume catapulted to more than 20.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/top-midday-gainers-184507995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","AMOD","BK4023","ATHE","TECX"],"gpt_icon":0},{"id":"2507676186","title":"Nasdaq Moves Lower; Meta Platforms Posts Strong Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2507676186","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507676186?lang=en_us&edition=fundamental","pubTime":"2025-01-31 01:34","pubTimestamp":1738258466,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/01/43347085/nasdaq-edges-lower-meta-platforms-posts-strong-sales","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TECX","NDAQ","UPS","NTCT","CRGX","ATHE","META",".IXIC","WHR"],"gpt_icon":1},{"id":"2507249406","title":"Dow Jumps Over 100 Points; Tesla Earnings Miss Views","url":"https://stock-news.laohu8.com/highlight/detail?id=2507249406","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507249406?lang=en_us&edition=fundamental","pubTime":"2025-01-30 23:03","pubTimestamp":1738249415,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/01/43340053/dow-jumps-over-100-points-tesla-earnings-miss-views","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TECX","SLXN","CLEU","PCOM","CRGX","AMOD","ATHE","TSLL","TSLA"],"gpt_icon":1},{"id":"2507629003","title":"Alterity Therapeutics Says ATH434 Showed Slowing of Clinical Progression in Phase 2 Multiple System Atrophy Study; Shares Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2507629003","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507629003?lang=en_us&edition=fundamental","pubTime":"2025-01-30 22:39","pubTimestamp":1738247954,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics  shares were sharply higher Thursday morning after the company said that its ATH434 lead candidate demonstrated 48% slowing of clinical progression in a phase 2 clinical trial in patients with early-stage multiple system atrophy.The result was achieved at the 50 mg dose at week 52 when compared with placebo, Alterity said.The company also said that ATH434 was well-tolerated, with no reported serious adverse events.Price: 5.48, Change: +2.49, Percent Change: +83.28","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ATHE","LENZ"],"gpt_icon":0},{"id":"2507647737","title":"Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2507647737","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507647737?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:35","pubTimestamp":1738240500,"startTime":"0","endTime":"0","summary":"– Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied –。– Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale –。– Key MRI Biomarker Shows Iron Stabilization in MSA Affected Brain Regions –。– ATH434 Demonstrated a Favorable Safety Profile –。– Webcast Held Yesterday with Access to the Recording Below –。“We are thrilled that ATH434 has demonstrated significant slowing of clinical progression and an excellent safety profile in this rare, rapidly progressive disease,” said David Stamler, M.D., Chief Executive Officer of Alterity. “Currently, there are no approved treatments that slow the progression of MSA and these results show that ATH434’s targeted iron engagement may truly have a disease modifying effect. The fact that we achieved statistical significance on the UMSARS is extremely meaningful because it assesses the functional areas affected in MSA and is the endpoint needed to support drug approval by the U.S. Food and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alterity-therapeutics-announces-positive-ath434-123500870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["ATH.AU","LENZ","ATHE","AE","BK7016","LU2125909916.SGD","LU1923622291.USD","BK4139","LU0728928796.USD","LU0053671581.USD","LU2125909759.SGD","LU1815336091.USD","LU0757428866.USD","MSA","BID.AU","BK4138","LU2211815571.USD","BK7067","BK4143"],"gpt_icon":0},{"id":"2506536239","title":"Alterity Therapeutics Ltd (ADR) trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2506536239","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506536239?lang=en_us&edition=fundamental","pubTime":"2025-01-28 06:55","pubTimestamp":1738018507,"startTime":"0","endTime":"0","summary":"17:51 EST Alterity Therapeutics (ATHE) Ltd (ADR) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-ltd-adr-trading-halted-news-pending-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-ltd-adr-trading-halted-news-pending-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","ATHE"],"gpt_icon":0},{"id":"2505854863","title":"Appendix 4C – Q2 FY25 Quarterly Cash Flow Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2505854863","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505854863?lang=en_us&edition=fundamental","pubTime":"2025-01-24 20:35","pubTimestamp":1737722100,"startTime":"0","endTime":"0","summary":"Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February 2025ATH434-201 trial in early-stage MSA completed in November 202","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/24/3014854/0/en/Appendix-4C-Q2-FY25-Quarterly-Cash-Flow-Report.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4143","LU1923622291.USD","BK4139","LU0757428866.USD","ATHE","LU0053671581.USD","LU2125909759.SGD","LU2211815571.USD","LU1815336091.USD","LU2125909916.SGD","LU0728928796.USD","MSA"],"gpt_icon":0},{"id":"2502113190","title":"Alterity CEO says ‘filled with optimism for 2025’","url":"https://stock-news.laohu8.com/highlight/detail?id=2502113190","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502113190?lang=en_us&edition=fundamental","pubTime":"2025-01-09 20:35","pubTimestamp":1736426135,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics (ATHE) issued a letter to shareholders from CEO David Stamler, stating in part: “As we again begin a new year, I am filled wi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alterity-ceo-says-filled-with-optimism-for-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alterity-ceo-says-filled-with-optimism-for-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ATHE"],"gpt_icon":0},{"id":"2502161380","title":"Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2502161380","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502161380?lang=en_us&edition=fundamental","pubTime":"2025-01-09 20:25","pubTimestamp":1736425500,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and SAN FRANCISCO, Jan. 09, 2025  -- Alterity Therapeutics  , a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to shareholders.As we again begin a new year, I am filled with optimism for 2025 and what lies ahead for Alterity Therapeutics.I want to express my sincere gratitude for your unwavering support and belief in our mission to develop disease-modifying therapies for those living with neurodegenerative diseases. Your investment in Alterity allows us to pursue groundbreaking research and bring hope to patients and families affected by these devastating conditions.2024 was a year of significant progress for Alterity. Most prominently, we completed our 12-month, double-blind Phase 2 clinical trial of ATH434 in early-stage Multiple System Atrophy . This milestone leads us to a topline data readout expected in late January or early February. Last July, we were pleased to report encoura","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alterity-therapeutics-issues-shareholder-letter-122500982.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0053671581.USD","ATH.AU","LU2125909759.SGD","LU0757428866.USD","BK4143","LU1815336091.USD","LU1923622291.USD","MSA","LENZ","BK4139","LU2125909916.SGD","LU0728928796.USD","ATHE"],"gpt_icon":0},{"id":"2491339984","title":"Alterity Therapeutics Initiated at Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2491339984","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491339984?lang=en_us&edition=fundamental","pubTime":"2024-12-13 00:53","pubTimestamp":1734022380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ATHE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2024 11:53 ET (16:53 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATHE","BK4139","LENZ","ATH.AU"],"gpt_icon":0},{"id":"2488198729","title":"Alterity Therapeutics completes last patient visit in ATH434-201 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2488198729","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488198729?lang=en_us&edition=fundamental","pubTime":"2024-12-04 20:40","pubTimestamp":1733316025,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics (ATHE) announced that the last patient in the ATH434-201 Phase 2 trial, a randomized, double-blind, placebo-controlled invest...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-completes-last-patient-visit-in-ath434-201-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-completes-last-patient-visit-in-ath434-201-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","ATHE"],"gpt_icon":0},{"id":"2488602651","title":"Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2488602651","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488602651?lang=en_us&edition=fundamental","pubTime":"2024-12-04 20:35","pubTimestamp":1733315700,"startTime":"0","endTime":"0","summary":"– ATH434 is a Disease Modifying Drug Candidate Targeting Alpha-Synuclein and Iron in Parkinsonian Disorders – – Topline Data Expected in Early 2025 – MELBOURNE, Australiaand SAN FRANCISCO, Dec.  04, 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/04/2991393/0/en/Alterity-Therapeutics-Completes-Last-Patient-Visit-in-ATH434-201-Phase-2-Clinical-Trial-in-Early-Stage-Multiple-System-Atrophy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0728928796.USD","MSA","ATHE","LU1815336091.USD","LU0757428866.USD","LENZ","BK4143","BK4139","LU2125909759.SGD","SSI","LU0053671581.USD","LU2125909916.SGD","LU1923622291.USD"],"gpt_icon":0},{"id":"2484943145","title":"Alterity Therapeutics appoints Abby Macnish Niven as secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=2484943145","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484943145?lang=en_us&edition=fundamental","pubTime":"2024-11-19 20:30","pubTimestamp":1732019423,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics (ATHE) has announced the appointment of Abby Macnish Niven as Alterity’s Company Secretary following her appointment as CFO o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-appoints-abby-macnish-niven-as-secretary?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-appoints-abby-macnish-niven-as-secretary?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATHE","BK4139","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alteritytherapeutics.com","stockEarnings":[{"period":"1week","weight":0.04},{"period":"1month","weight":0.3341},{"period":"3month","weight":3},{"period":"6month","weight":2.1799},{"period":"1year","weight":1.199},{"period":"ytd","weight":0.3353}],"compareEarnings":[{"period":"1week","weight":0.0149},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0409},{"period":"6month","weight":0.0999},{"period":"1year","weight":0.2145},{"period":"ytd","weight":0.0403}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.565217,"avgChangeRate":0.097263},{"month":2,"riseRate":0.347826,"avgChangeRate":-0.065161},{"month":3,"riseRate":0.409091,"avgChangeRate":0.005611},{"month":4,"riseRate":0.5,"avgChangeRate":-0.019094},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.055947},{"month":6,"riseRate":0.318182,"avgChangeRate":0.026025},{"month":7,"riseRate":0.545455,"avgChangeRate":0.089249},{"month":8,"riseRate":0.590909,"avgChangeRate":0.068907},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.035667},{"month":10,"riseRate":0.304348,"avgChangeRate":-0.073881},{"month":11,"riseRate":0.434783,"avgChangeRate":-0.016008},{"month":12,"riseRate":0.304348,"avgChangeRate":0.034434}],"exchange":"NASDAQ","name":"Alterity Therapeutics Limited","nameEN":"Alterity Therapeutics Limited"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alterity Therapeutics Limited(ATHE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alterity Therapeutics Limited(ATHE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alterity Therapeutics Limited,ATHE,Alterity Therapeutics Limited股票,Alterity Therapeutics Limited股票老虎,Alterity Therapeutics Limited股票老虎国际,Alterity Therapeutics Limited行情,Alterity Therapeutics Limited股票行情,Alterity Therapeutics Limited股价,Alterity Therapeutics Limited股市,Alterity Therapeutics Limited股票价格,Alterity Therapeutics Limited股票交易,Alterity Therapeutics Limited股票购买,Alterity Therapeutics Limited股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alterity Therapeutics Limited(ATHE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alterity Therapeutics Limited(ATHE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}